The following abstracts represent the presentations given at IWWM-8 (London-2014), special session, Great Debates in Waldenstrom's Macroglobulinemia:

Session Chairs: V. Leblond & S. D'Sa

Should MYD88 and CXCR4 be tested in all WM patients? [YES] X. Leleu (France)

Should MYD88 and CXCR4 be tested in all WM patients? [NO] E. Kimby (Sweden)

Should bendamustine or ibrutinib be the first salvage in WM? [BEND] M. Rummel (Germany(

Should bendamustine or ibrutinib be the first salvage in WM? [IBRU] L. Palomba (USA)

Should carfilzomib be given instead of bortezomib for WM? [YES] I. Ghobrial (USA)

Should carfilzomib be given instead of bortezomib for WM? [NO] M. Dimopoulos (Greece)

Are response criteria for WM adequate? [YES] R. Owen (UK)

Are response criteria for WM adequate? [NO] E. Morra (Italy)